What is Amunix Pharmaceuticals?
Founded in 2006 and headquartered in Mountain View, California, Amunix Pharmaceuticals is a specialized biopharmaceutical entity dedicated to the development of innovative cancer therapies. The company leverages advanced protein engineering to create therapeutics designed to improve the efficacy and safety profiles of oncology treatments. By focusing on precision medicine, Amunix has established itself as a key player in the biotechnology sector, attracting significant interest from top-tier venture capital firms and global investment managers who prioritize high-impact life science innovation.
How much funding has Amunix Pharmaceuticals raised?
Amunix Pharmaceuticals has raised a total of $190M across 2 funding rounds:
Series A
$73M
Series B
$117M
Series A (2020): $73M with participation from Omega Funds, Polaris Partners, Longitude Capital, Venrock, Delian Capital, Casdin Capital, Two River, Redmile Group, and Frazier Healthcare Partners
Series B (2021): $117M led by ArrowMark Partners, Avidity Partners, Franklin Templeton, Omega Funds, The Clough Global Long/Short Fund, Polaris Partners, Longitude Capital, Venrock, Casdin Capital, BlackRock, Viking Global Investors, Caas Capital Management, Bain Capital, Janus Henderson Investors, Redmile Group, and Frazier Healthcare Partners
Key Investors in Amunix Pharmaceuticals
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors, providing deep operational expertise and strategic resources to foster innovation.
Venrock
A historic venture capital firm with a long track record of supporting high-growth technology and healthcare ventures, known for its deep industry expertise and commitment to scaling startups.
Longitude Capital
A healthcare-focused venture capital firm that invests in biotechnology and medical technology, pairing sector expertise with flexible capital to help innovators improve patient care.
What's next for Amunix Pharmaceuticals?
With the infusion of capital from its latest financing round, Amunix Pharmaceuticals is poised to advance its lead candidates through critical clinical milestones. The strategic focus will likely center on optimizing its therapeutic platform to address unmet needs in the cancer industry, while simultaneously strengthening its intellectual property portfolio. As the company matures, the emphasis will shift toward operational scaling and potential strategic partnerships, ensuring that its novel drug candidates move efficiently through the regulatory approval process. The continued support from institutional heavyweights suggests a long-term commitment to building a sustainable, high-growth enterprise capable of delivering transformative patient outcomes.
See full Amunix Pharmaceuticals company page
